Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SPIRIG PHARMA AG

Home Clinical Trial Sponsors and OrganizationsSPIRIG PHARMA AG

SPIRIG PHARMA AG

ACTIVE

20 AVENUE ANDRE PROTHIN, Courbevoie, Île-de-France, FranceSubsidiary

Part of galderma pharma sa

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

7 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1

12.5%

Phase 3

1

12.5%

Trial Status Distribution

Active, not recruiting

7

87.5%

Completed

1

12.5%

Clinical Trials

Trials sponsored by this organization (8)

Observational (non-interventional), follow-up trial assessing long-term local tolerability and efficacy (recurrence rate) of resiquimod gel in patients treated for actinic keratosis.

Active, not recruiting

Dec 201280 participants

Prospective clinical trial, in which the test product (a cream containing 2% of Sertaconazol a known anti-mycotic ingredient) or the comparator product (cream without any active ingredient) are being dispatched randomly to the patients without that they or their physicians know which product they receive. Objective is to explore the anti-itch potential of the test product in atopic dermatitis as well as its safety and its local tolerability.

Active, not recruiting

Open label, non-comparative trial, conducted at two trial sites exploring efficacy and safety of external and local application of resiquimod gel (0.06%) in patients with nodular basal cell cancer (nBCC).

Active, not recruiting

Sep 201230 participants

Prospective, randomized, partly blinded, in part placebo-controlled, multicenter, dose-finding trial exploring safety, tolerability and efficacy of a topical resiquimod gel in patients with multiple actinic keratosis lesions

Active, not recruiting

Nov 2011208 participants

A controlled, randomized, evaluator-blinded study for the assessment of efficacy and safety of Imazol® Paste and Multilind® Heilsalbe in infants with diaper dermatitis

Active, not recruiting

Apr 2006102 participants

Efficacy and safety of topically applied cyclodextrin gel (Spirig Pharma) in the treatment of recurrent genital herpes simplex virus infections: a randomised, double-blind, placebo-controlled, multicentre trial. - NA

Active, not recruiting

Oct 2005200 participants

ntersuchung der Wirksamkeit einer glycerinhaltigen Creme bei der Behandlung von Atopischer Dermatitis. Kontrolliert, randomisierte Doppel-Blind-Studie.

Active, not recruiting

May 200524 participants

An open, multicentre, randomised, inter-individual comparative, prospective clinical trial with MD-3511356 versus standard sun protection measures in immunosuppressed outpatients after solid organ transplantations for the prevention of UV-induced infections and carcinogenic skin alterations

40 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials8
Approvals
News

Back to Organizations